They are not effective, have little scientific evidence to back up their claims, and are misleading because they do not contain any GLP-1 agonists
Finally, the combination of a GLP-1 receptor agonist and amylin agonism by cagrilintide/semaglutide is currently under investigation (Table 1)
Theyve been around for decades, helping treat patients with type 2 diabetes and short bowel syndrome, but when it was discovered that they could also help patients with obesity, they became several household names Ozempic, Wegovy, Mounjaro, etc
References to Wegovy, Ozempic, Rybelsus, Mounjaro, or Saxenda, or other GLP-1 brands, are informational only
Bioactive Components in Moringa Oleifera Leaves Protect against Chronic Disease
In June, a paper in JAMA Ophthalmology looked at age-related macular degeneration in people with Type 2 diabetes who were taking GLP-1 drugs